Keywords: Amgen, Vectibix, Head and neck cancer, Phase III

Top-line results of Ph III head and neck cancer trial with Amgen’s Vectibix disappoint

Article | 12 August 2010

Leading US biotechnology firm Amgen announced disappointing top-line results from a randomized Phase III trial evaluating Vectibix (panitumumab) as a ...

Enjoying this article? To continue reading you need to login or subscribe.

Subscribe now
for unlimited access to all articles

Subscriptions are £60 per month, pay as you go.
Find out more details.

Already a subscriber? Click here to log in

Related Companies

Amgen

Go to company listing

Related Drugs

Vectibix

Go to drug listing